Paradigm Biopharmaceuticals Ltd. PAR
ASX · Australia · Health Technology
AUD 0.24500.00 (0.00%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The osteoarthritis market is projected to grow from 2026 to 2036, driven by an aging population and rising disease prevalence. The expected launch of emerging therapies such as LEVI-04 (Levicept), ZILOSUL (Paradigm Biopharmaceuticals), TissueGene-C (TG-C) (Kolon TissueGene), AMZ001 (Amzell), SAR446959 (Sanofi), PCRX-201 (enekinragene inzadenovec) (Pacira BioSciences), and others is further supporting market expansion.New York, USA, June 15, 2026 (GLOBE NEWSWIRE) -- Osteoarthritis Market Expected
With the business potentially at an important milestone, we thought we'd take a closer look at Paradigm...
Paradigm Biopharmaceuticals Limited recently presented at the Ignite Investment Summit, held from October 15 to October 16, 2025, at The Grand Ballroom, Grand Hyatt Hong Kong, featuring a presentation by Founder and Executive Chairman Paul John Rennie. This high-profile summit appearance drew attention to anticipated updates from Paradigm Biopharmaceuticals’ leadership, which could influence perceptions of the company’s outlook. We’ll review how investor anticipation of new insights from...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.